Optimer Pharmaceuticals



		Subscribe to RSS feed 2010 \| 2009 \| 2008 \| 2007 \| 2006 \| 2005 \| 2004 \| 2002 \| 2001 \| (12.16.2009) SAN DIEGO, CA Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference (12.3.2009) SAN DIEGO, CA Optimer Pharmaceuticals Appoints Robert L. Zerbe, M.D. to its Board of Directors (11.24.2009) SAN DIEGO Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference (11.12.2009) SAN DIEGO Optimer Pharmaceuticals Completes Enrollment in Second Fidaxomicin Phase 3 Clinical Trial in Patients with Clostridium difficile Infection (11.3.2009) SAN DIEGO, CA Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results (10.31.2009) SAN DIEGO Additional Data from Fidaxomicins Phase 3 Study for Clostridium difficile infection (CDI) Presented at IDSA Annual Meeting (10.26.2009) SAN DIEGO, CA Optimer Pharmaceuticals to Present at November 2009 Investor Conferences (10.19.2009) SAN DIEGO Optimer Pharmaceuticals Announces Presentations of Additional Data from the Fidaxomicin North American Phase 3 Trial at Upcoming IDSA Annual Meeting (9.28.2009) SAN DIEGO Optimer Pharmaceuticals to Present at October 2009 Investor Conferences (9.16.2009) SAN FRANCISCO VIDEO Medical News from ICAAC: InFocus on Hospital-Related Infection Control (9.15.2009) SAN DIEGO Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) (9.14.2009) SAN DIEGO Data from Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (9.3.2009) SAN DIEGO Optimer Pharmaceuticals to Present at September 2009 Investor Conferences (9.2.2009) SAN DIEGO Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting (8.5.2009) SAN DIEGO Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results (8.4.2009) SAN DIEGO Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference (6.4.2009) SAN DIEGO Optimer Pharmaceuticals to Present at June 2009 Investor Conferences (6.2.2009) SAN DIEGO Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin versus Vancocin in Subgroup Analyses from its Phase 3 Study for the Treatment of CDI (5.17.2009) SAN DIEGO, CA Optimer Pharmaceuticals Presents Results from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (5.7.2009) SAN DIEGO Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results (4.13.2009) SAN DIEGO Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin (3.11.2009) SAN DIEGO Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Financial Results (3.9.2009) SAN DIEGO Optimer Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference (3.5.2009) SAN DIEGO Optimer Pharmaceuticals to Raise $32.9 Million in Registered Direct Offering (3.3.2009) SAN DIEGO Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results (3.2.2009) SAN DIEGO Optimer Pharmaceuticals to Accelerate European Filing of Fidaxomicin (OPT-80) (2.24.2009) SAN DIEGO Optimer Pharmaceuticals Announces Positive Results from Second Phase 3 Study of Prulifloxacin for Infectious Diarrhea in Travelers (2.23.2009) SAN DIEGO, CA Optimer Pharmaceuticals Appoints Industry Veterans Francois-Xavier Frapaise as Chief Scientific Officer and Peter E. Grebow to its Board of Directors

(12.16.2009) SAN DIEGO, CA

Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, CA – December 16, 2009 - Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) is scheduled to present at the 28^th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday, January 13, 2010. Michael N. Chang, Optimer’s President and Chief Executive Officer, will present at 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time).

A live audio webcast of this presentation will be accessible on the Investors page of the Company’s website at www.optimerpharma.com. Replays of this presentation will be available at the same location for 30 days following the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Pruvel™ (prulifloxacin) is an antibiotic which has completed two Phase 3 clinical trials for the treatment of infectious diarrhea in travelers. Additional information can be found at http://www.optimerpharma.com.

Contacts

Optimer Pharmaceuticals, Inc.

Christina Donaghy, Corporate Communications Manager

John D. Prunty, Chief Financial Officer & VP Finance

858-909-0736

Porter Novelli Life Sciences

Jason I. Spark, Vice President

619-849-6005